CDKN2A and neoplasm: We examined the prognostic significance of additional CDKN2A/B inactivating events, including nonsynonymous mutations and allele-specific copy number alterations (ASCNA) by analyzing 347 prospectively tumor-matched normal sequenced IDHA (347 patients, supplemental table 1) using FACETS (Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing), a SNP-based algorithm to assess ASCNA across genomic targets [8], with validation using The Cancer Genome Atlas (TCGA, 188 tumors/patients, supplemental methods).